Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus evening tofacitinib XR chronotherapy in rheumatoid arthritis and psoriatic arthritis
NL-OMON59198Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (2 arms), sponsored by Erasmus MC. Primary endpoint: Difference in RAPID-3 score between morning and evening dosing after 3 months. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON59198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59198.